Mersana Therapeutics Inc (NASDAQ: MRSN) Stock: Can It Surge Further?

In the last trading session, 1.08 million shares of the Mersana Therapeutics Inc (NASDAQ:MRSN) were traded, and its beta was 1.48. Most recently the company’s share price was $1.56, and it changed around $0.15 or 10.64% from the last close, which brings the market valuation of the company to $191.37M. MRSN currently trades at a discount to its 52-week high of $6.28, offering almost -302.56% off that amount. The share price’s 52-week low was $1.07, which indicates that the current value has risen by an impressive 31.41% since then. We note from Mersana Therapeutics Inc’s average daily trading volume that its 10-day average is 1.45 million shares, with the 3-month average coming to 1.38 million.

Mersana Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.44. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended MRSN as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Mersana Therapeutics Inc (NASDAQ:MRSN) trade information

Instantly MRSN has showed a green trend with a performance of 10.64% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.5800 on recent trading dayincreased the stock’s daily price by 1.27%. The company’s shares are currently down -32.76% year-to-date, but still up 19.08% over the last five days. On the other hand, Mersana Therapeutics Inc (NASDAQ:MRSN) is -21.21% down in the 30-day period. We can see from the shorts that 9.11 million shares have been sold at a short interest cover period of 7.89 day(s).

The consensus price target as assigned by Wall Street analysts is $3, which translates to bulls needing to increase their stock price by 48.0% from its current value. Analyst projections state that MRSN is forecast to be at a low of $3 and a high of $3.

Mersana Therapeutics Inc (MRSN) estimates and forecasts

Mersana Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -58.84 percent over the past six months and at a 57.43% annual growth rate that is well above the industry average of 18.30%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 11.93%.

MRSN Dividends

Mersana Therapeutics Inc’s next quarterly earnings report is expected to be released on 2024-Nov-05.

Mersana Therapeutics Inc (NASDAQ:MRSN)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 1.35% of Mersana Therapeutics Inc shares, and 94.62% of them are in the hands of institutional investors. The stock currently has a share float of 95.93%. Mersana Therapeutics Inc stock is held by 157.0 institutions, with ECOR1 CAPITAL, LLC being the largest institutional investor. By 2024-06-30, it held 15.9479% of the shares, which is about 19.36 million shares worth $38.92 million.

VR ADVISER, LLC, with 9.3292% or 11.33 million shares worth $22.77 million as of 2024-06-30, holds the second largest percentage of outstanding shares.

Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Mar 31, 2024 . The former held 3.22 shares worth $5.03 million, making up 2.63% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 2.81 shares worth around $4.39 million, which represents about 2.29% of the total shares outstanding.